Aceragen, Inc.

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, VRTX has a market cap of 99B. Regarding current trading prices, ACGN is priced at $0.38, while VRTX trades at $385.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas VRTX's P/E ratio is 27.43. In terms of profitability, ACGN's ROE is -0.68%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, ACGN is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check VRTX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, REGN has a market cap of 57.8B. Regarding current trading prices, ACGN is priced at $0.38, while REGN trades at $555.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas REGN's P/E ratio is 13.99. In terms of profitability, ACGN's ROE is -0.68%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ACGN is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check REGN's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ALNY has a market cap of 56.1B. Regarding current trading prices, ACGN is priced at $0.38, while ALNY trades at $428.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ALNY's P/E ratio is -173.34. In terms of profitability, ACGN's ROE is -0.68%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, ACGN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ALNY's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ACGN is priced at $0.38, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ACGN's ROE is -0.68%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ACGN is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check SGEN's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ARGX has a market cap of 41.2B. Regarding current trading prices, ACGN is priced at $0.38, while ARGX trades at $673.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ARGX's P/E ratio is 34.22. In terms of profitability, ACGN's ROE is -0.68%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, ACGN is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ARGX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, BNTX has a market cap of 26.8B. Regarding current trading prices, ACGN is priced at $0.38, while BNTX trades at $111.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas BNTX's P/E ratio is -67.45. In terms of profitability, ACGN's ROE is -0.68%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, ACGN is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check BNTX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, SMMT has a market cap of 21.2B. Regarding current trading prices, ACGN is priced at $0.38, while SMMT trades at $28.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas SMMT's P/E ratio is -83.80. In terms of profitability, ACGN's ROE is -0.68%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, ACGN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check SMMT's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, RPRX has a market cap of 20.9B. Regarding current trading prices, ACGN is priced at $0.38, while RPRX trades at $37.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas RPRX's P/E ratio is 15.14. In terms of profitability, ACGN's ROE is -0.68%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, ACGN is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check RPRX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ACGN is priced at $0.38, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ACGN's ROE is -0.68%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, ACGN is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check BGNE's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ACGN is priced at $0.38, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ACGN's ROE is -0.68%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, ACGN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check DNA-WT's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, INCY has a market cap of 15.2B. Regarding current trading prices, ACGN is priced at $0.38, while INCY trades at $77.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas INCY's P/E ratio is 18.36. In terms of profitability, ACGN's ROE is -0.68%, compared to INCY's ROE of +0.34%. Regarding short-term risk, ACGN is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check INCY's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, UTHR has a market cap of 13.7B. Regarding current trading prices, ACGN is priced at $0.38, while UTHR trades at $302.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas UTHR's P/E ratio is 11.79. In terms of profitability, ACGN's ROE is -0.68%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ACGN is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check UTHR's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, GMAB has a market cap of 13.2B. Regarding current trading prices, ACGN is priced at $0.38, while GMAB trades at $21.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas GMAB's P/E ratio is 12.65. In terms of profitability, ACGN's ROE is -0.68%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, ACGN is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check GMAB's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ACGN is priced at $0.38, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ACGN's ROE is -0.68%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ACGN is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check KRTX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, ACGN is priced at $0.38, while BMRN trades at $60.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas BMRN's P/E ratio is 17.90. In terms of profitability, ACGN's ROE is -0.68%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, ACGN is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check BMRN's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ASND has a market cap of 11B. Regarding current trading prices, ACGN is priced at $0.38, while ASND trades at $182.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ASND's P/E ratio is -27.09. In terms of profitability, ACGN's ROE is -0.68%, compared to ASND's ROE of +1.91%. Regarding short-term risk, ACGN is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ASND's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MRNA has a market cap of 10.4B. Regarding current trading prices, ACGN is priced at $0.38, while MRNA trades at $26.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MRNA's P/E ratio is -3.56. In terms of profitability, ACGN's ROE is -0.68%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, ACGN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MRNA's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, EXEL has a market cap of 10.2B. Regarding current trading prices, ACGN is priced at $0.38, while EXEL trades at $37.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas EXEL's P/E ratio is 18.13. In terms of profitability, ACGN's ROE is -0.68%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, ACGN is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check EXEL's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ACGN is priced at $0.38, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ACGN's ROE is -0.68%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ACGN is less volatile compared to RXDX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check RXDX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, ACGN is priced at $0.38, while VRNA trades at $105.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas VRNA's P/E ratio is -52.69. In terms of profitability, ACGN's ROE is -0.68%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, ACGN is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check VRNA's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ACGN is priced at $0.38, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ACGN's ROE is -0.68%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, ACGN is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check IMGN's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, BBIO has a market cap of 8.5B. Regarding current trading prices, ACGN is priced at $0.38, while BBIO trades at $44.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas BBIO's P/E ratio is -12.59. In terms of profitability, ACGN's ROE is -0.68%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, ACGN is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check BBIO's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ACGN is priced at $0.38, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ACGN's ROE is -0.68%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, ACGN and BPMC have similar daily volatility (0.00).Check BPMC's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ACGN is priced at $0.38, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas CERE's P/E ratio is -16.47. In terms of profitability, ACGN's ROE is -0.68%, compared to CERE's ROE of -0.43%. Regarding short-term risk, ACGN is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check CERE's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, ACGN is priced at $0.38, while ROIV trades at $11.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ROIV's P/E ratio is -15.54. In terms of profitability, ACGN's ROE is -0.68%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, ACGN is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ROIV's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, ACGN is priced at $0.38, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, ACGN's ROE is -0.68%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, ACGN is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ROIVW's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, TECH has a market cap of 7.8B. Regarding current trading prices, ACGN is priced at $0.38, while TECH trades at $49.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas TECH's P/E ratio is 60.08. In terms of profitability, ACGN's ROE is -0.68%, compared to TECH's ROE of +0.06%. Regarding short-term risk, ACGN is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check TECH's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, HALO has a market cap of 7.7B. Regarding current trading prices, ACGN is priced at $0.38, while HALO trades at $62.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas HALO's P/E ratio is 16.56. In terms of profitability, ACGN's ROE is -0.68%, compared to HALO's ROE of +1.22%. Regarding short-term risk, ACGN is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check HALO's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MDGL has a market cap of 7.5B. Regarding current trading prices, ACGN is priced at $0.38, while MDGL trades at $338.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MDGL's P/E ratio is -18.94. In terms of profitability, ACGN's ROE is -0.68%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, ACGN is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MDGL's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, CORT has a market cap of 7.4B. Regarding current trading prices, ACGN is priced at $0.38, while CORT trades at $70.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas CORT's P/E ratio is 62.96. In terms of profitability, ACGN's ROE is -0.68%, compared to CORT's ROE of +0.20%. Regarding short-term risk, ACGN is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check CORT's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, RVMD has a market cap of 6.8B. Regarding current trading prices, ACGN is priced at $0.38, while RVMD trades at $36.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas RVMD's P/E ratio is -9.14. In terms of profitability, ACGN's ROE is -0.68%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, ACGN is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check RVMD's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ACGN is priced at $0.38, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas RETA's P/E ratio is -66.29. In terms of profitability, ACGN's ROE is -0.68%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ACGN is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check RETA's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, IONS has a market cap of 6.5B. Regarding current trading prices, ACGN is priced at $0.38, while IONS trades at $40.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas IONS's P/E ratio is -23.12. In terms of profitability, ACGN's ROE is -0.68%, compared to IONS's ROE of -0.45%. Regarding short-term risk, ACGN is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check IONS's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, JAZZ has a market cap of 6.4B. Regarding current trading prices, ACGN is priced at $0.38, while JAZZ trades at $105.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas JAZZ's P/E ratio is 14.39. In terms of profitability, ACGN's ROE is -0.68%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, ACGN is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check JAZZ's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, ACGN is priced at $0.38, while RYTM trades at $90.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas RYTM's P/E ratio is -29.90. In terms of profitability, ACGN's ROE is -0.68%, compared to RYTM's ROE of -1.78%. Regarding short-term risk, ACGN is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check RYTM's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, RNA has a market cap of 5.8B. Regarding current trading prices, ACGN is priced at $0.38, while RNA trades at $48.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas RNA's P/E ratio is -16.09. In terms of profitability, ACGN's ROE is -0.68%, compared to RNA's ROE of -0.27%. Regarding short-term risk, ACGN is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check RNA's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, ACGN is priced at $0.38, while NUVL trades at $77.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas NUVL's P/E ratio is -17.47. In terms of profitability, ACGN's ROE is -0.68%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, ACGN is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check NUVL's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ACGN is priced at $0.38, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ACGN's ROE is -0.68%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ACGN is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ABCM's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ACGN is priced at $0.38, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ACGN's ROE is -0.68%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ACGN is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ISEE's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ABVX has a market cap of 5.2B. Regarding current trading prices, ACGN is priced at $0.38, while ABVX trades at $69.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ABVX's P/E ratio is -20.20. In terms of profitability, ACGN's ROE is -0.68%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, ACGN is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ABVX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, ACGN is priced at $0.38, while AXSM trades at $103.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas AXSM's P/E ratio is -20.41. In terms of profitability, ACGN's ROE is -0.68%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, ACGN is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check AXSM's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, ACGN is priced at $0.38, while CRSP trades at $56.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas CRSP's P/E ratio is -10.43. In terms of profitability, ACGN's ROE is -0.68%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, ACGN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check CRSP's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MRUS has a market cap of 4.9B. Regarding current trading prices, ACGN is priced at $0.38, while MRUS trades at $65.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MRUS's P/E ratio is -15.75. In terms of profitability, ACGN's ROE is -0.68%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, ACGN is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MRUS's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ACGN is priced at $0.38, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ACGN's ROE is -0.68%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, ACGN is less volatile compared to ALPN. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ALPN's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ADMA has a market cap of 4.4B. Regarding current trading prices, ACGN is priced at $0.38, while ADMA trades at $18.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ADMA's P/E ratio is 22.07. In terms of profitability, ACGN's ROE is -0.68%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, ACGN is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ADMA's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, TGTX has a market cap of 4.4B. Regarding current trading prices, ACGN is priced at $0.38, while TGTX trades at $27.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas TGTX's P/E ratio is 72.89. In terms of profitability, ACGN's ROE is -0.68%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, ACGN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check TGTX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, ACGN is priced at $0.38, while ALKS trades at $26.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ALKS's P/E ratio is 12.83. In terms of profitability, ACGN's ROE is -0.68%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, ACGN is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ALKS's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, SLNO has a market cap of 4.3B. Regarding current trading prices, ACGN is priced at $0.38, while SLNO trades at $81.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas SLNO's P/E ratio is -17.13. In terms of profitability, ACGN's ROE is -0.68%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, ACGN is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check SLNO's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ZLAB has a market cap of 4.3B. Regarding current trading prices, ACGN is priced at $0.38, while ZLAB trades at $38.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ZLAB's P/E ratio is -15.49. In terms of profitability, ACGN's ROE is -0.68%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, ACGN is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ZLAB's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, PCVX has a market cap of 4.3B. Regarding current trading prices, ACGN is priced at $0.38, while PCVX trades at $33.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas PCVX's P/E ratio is -8.27. In terms of profitability, ACGN's ROE is -0.68%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, ACGN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check PCVX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, AKRO has a market cap of 4.2B. Regarding current trading prices, ACGN is priced at $0.38, while AKRO trades at $52.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas AKRO's P/E ratio is -14.08. In terms of profitability, ACGN's ROE is -0.68%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, ACGN is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check AKRO's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ACGN is priced at $0.38, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas OPT's P/E ratio is -1.52. In terms of profitability, ACGN's ROE is -0.68%, compared to OPT's ROE of +2.60%. Regarding short-term risk, ACGN and OPT have similar daily volatility (0.00).Check OPT's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, CYTK has a market cap of 4.2B. Regarding current trading prices, ACGN is priced at $0.38, while CYTK trades at $35.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas CYTK's P/E ratio is -6.64. In terms of profitability, ACGN's ROE is -0.68%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, ACGN is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check CYTK's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ACGN is priced at $0.38, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ACGN's ROE is -0.68%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ACGN is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MRTX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, ACGN is priced at $0.38, while PTCT trades at $51.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas PTCT's P/E ratio is 7.89. In terms of profitability, ACGN's ROE is -0.68%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, ACGN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check PTCT's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, TLX has a market cap of 4.1B. Regarding current trading prices, ACGN is priced at $0.38, while TLX trades at $11.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas TLX's P/E ratio is 133.00. In terms of profitability, ACGN's ROE is -0.68%, compared to TLX's ROE of +0.06%. Regarding short-term risk, ACGN is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check TLX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ACAD has a market cap of 4B. Regarding current trading prices, ACGN is priced at $0.38, while ACAD trades at $23.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ACAD's P/E ratio is 17.37. In terms of profitability, ACGN's ROE is -0.68%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, ACGN is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ACAD's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, AAPG has a market cap of 4B. Regarding current trading prices, ACGN is priced at $0.38, while AAPG trades at $42.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas AAPG's P/E ratio is -57.89. In terms of profitability, ACGN's ROE is -0.68%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, ACGN is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check AAPG's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, KRYS has a market cap of 3.9B. Regarding current trading prices, ACGN is priced at $0.38, while KRYS trades at $136.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas KRYS's P/E ratio is 27.59. In terms of profitability, ACGN's ROE is -0.68%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, ACGN is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check KRYS's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, ACGN is priced at $0.38, while ACLX trades at $70.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ACLX's P/E ratio is -23.64. In terms of profitability, ACGN's ROE is -0.68%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, ACGN is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ACLX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ACGN is priced at $0.38, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ACGN's ROE is -0.68%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ACGN is less volatile compared to RYZB. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check RYZB's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ACGN is priced at $0.38, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ACGN's ROE is -0.68%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ACGN is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check CBAY's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, ACGN is priced at $0.38, while VKTX trades at $31.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas VKTX's P/E ratio is -20.70. In terms of profitability, ACGN's ROE is -0.68%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, ACGN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check VKTX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ACGN is priced at $0.38, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ACGN's ROE is -0.68%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, ACGN and SWTX have similar daily volatility (0.00).Check SWTX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MTSR has a market cap of 3.5B. Regarding current trading prices, ACGN is priced at $0.38, while MTSR trades at $33.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MTSR's P/E ratio is -11.53. In terms of profitability, ACGN's ROE is -0.68%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, ACGN is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MTSR's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, ACGN is priced at $0.38, while LEGN trades at $37.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas LEGN's P/E ratio is -31.92. In terms of profitability, ACGN's ROE is -0.68%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, ACGN is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check LEGN's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MLTX has a market cap of 3.3B. Regarding current trading prices, ACGN is priced at $0.38, while MLTX trades at $52.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MLTX's P/E ratio is -18.91. In terms of profitability, ACGN's ROE is -0.68%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, ACGN is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MLTX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, ACGN is priced at $0.38, while PTGX trades at $53.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas PTGX's P/E ratio is 69.08. In terms of profitability, ACGN's ROE is -0.68%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, ACGN is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check PTGX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, SRRK has a market cap of 3.3B. Regarding current trading prices, ACGN is priced at $0.38, while SRRK trades at $34.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas SRRK's P/E ratio is -13.57. In terms of profitability, ACGN's ROE is -0.68%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, ACGN is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check SRRK's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, APLS has a market cap of 3B. Regarding current trading prices, ACGN is priced at $0.38, while APLS trades at $23.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas APLS's P/E ratio is -12.97. In terms of profitability, ACGN's ROE is -0.68%, compared to APLS's ROE of -1.16%. Regarding short-term risk, ACGN is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check APLS's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, KYMR has a market cap of 2.9B. Regarding current trading prices, ACGN is priced at $0.38, while KYMR trades at $41.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas KYMR's P/E ratio is -13.30. In terms of profitability, ACGN's ROE is -0.68%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, ACGN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check KYMR's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, ACGN is priced at $0.38, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MORF's P/E ratio is -14.88. In terms of profitability, ACGN's ROE is -0.68%, compared to MORF's ROE of -0.22%. Regarding short-term risk, ACGN is less volatile compared to MORF. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MORF's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, ACGN is priced at $0.38, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MOR's P/E ratio is -12.64. In terms of profitability, ACGN's ROE is -0.68%, compared to MOR's ROE of -1.84%. Regarding short-term risk, ACGN is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MOR's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, LGND has a market cap of 2.7B. Regarding current trading prices, ACGN is priced at $0.38, while LGND trades at $142.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas LGND's P/E ratio is -19.56. In terms of profitability, ACGN's ROE is -0.68%, compared to LGND's ROE of -0.16%. Regarding short-term risk, ACGN is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check LGND's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, ACGN is priced at $0.38, while IMVT trades at $15.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas IMVT's P/E ratio is -5.85. In terms of profitability, ACGN's ROE is -0.68%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, ACGN is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check IMVT's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, ACGN is priced at $0.38, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas KDNY's P/E ratio is -12.47. In terms of profitability, ACGN's ROE is -0.68%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, ACGN is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check KDNY's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, CRNX has a market cap of 2.7B. Regarding current trading prices, ACGN is priced at $0.38, while CRNX trades at $28.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas CRNX's P/E ratio is -7.51. In terms of profitability, ACGN's ROE is -0.68%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, ACGN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check CRNX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, ACGN is priced at $0.38, while CPRX trades at $21.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas CPRX's P/E ratio is 13.88. In terms of profitability, ACGN's ROE is -0.68%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, ACGN is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check CPRX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, RARE has a market cap of 2.7B. Regarding current trading prices, ACGN is priced at $0.38, while RARE trades at $28.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas RARE's P/E ratio is -4.81. In terms of profitability, ACGN's ROE is -0.68%, compared to RARE's ROE of -1.86%. Regarding short-term risk, ACGN is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check RARE's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, NAMS has a market cap of 2.7B. Regarding current trading prices, ACGN is priced at $0.38, while NAMS trades at $23.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas NAMS's P/E ratio is -12.84. In terms of profitability, ACGN's ROE is -0.68%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, ACGN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check NAMS's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, ACGN is priced at $0.38, while MIRM trades at $53.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MIRM's P/E ratio is -33.16. In terms of profitability, ACGN's ROE is -0.68%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, ACGN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MIRM's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, XENE has a market cap of 2.6B. Regarding current trading prices, ACGN is priced at $0.38, while XENE trades at $34.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas XENE's P/E ratio is -10.64. In terms of profitability, ACGN's ROE is -0.68%, compared to XENE's ROE of -0.32%. Regarding short-term risk, ACGN is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check XENE's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, ACGN is priced at $0.38, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas MYOV's P/E ratio is -14.05. In terms of profitability, ACGN's ROE is -0.68%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, ACGN is less volatile compared to MYOV. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check MYOV's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, NAMSW has a market cap of 2.6B. Regarding current trading prices, ACGN is priced at $0.38, while NAMSW trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas NAMSW's P/E ratio is N/A. In terms of profitability, ACGN's ROE is -0.68%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, ACGN is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check NAMSW's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, ACGN is priced at $0.38, while KNSA trades at $32.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas KNSA's P/E ratio is 654.40. In terms of profitability, ACGN's ROE is -0.68%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, ACGN is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check KNSA's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, ACGN is priced at $0.38, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas PRVB's P/E ratio is -16.43. In terms of profitability, ACGN's ROE is -0.68%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, ACGN is less volatile compared to PRVB. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check PRVB's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, ACGN is priced at $0.38, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas LBPH's P/E ratio is -26.66. In terms of profitability, ACGN's ROE is -0.68%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, ACGN and LBPH have similar daily volatility (0.00).Check LBPH's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, RXRX has a market cap of 2.3B. Regarding current trading prices, ACGN is priced at $0.38, while RXRX trades at $5.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas RXRX's P/E ratio is -3.03. In terms of profitability, ACGN's ROE is -0.68%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, ACGN is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check RXRX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, ACGN is priced at $0.38, while CNTA trades at $17.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas CNTA's P/E ratio is -9.12. In terms of profitability, ACGN's ROE is -0.68%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, ACGN is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check CNTA's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, ACGN is priced at $0.38, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas DICE's P/E ratio is -21.91. In terms of profitability, ACGN's ROE is -0.68%, compared to DICE's ROE of +0.56%. Regarding short-term risk, ACGN is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check DICE's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, ACGN is priced at $0.38, while ARWR trades at $16.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas ARWR's P/E ratio is -13.15. In terms of profitability, ACGN's ROE is -0.68%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, ACGN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check ARWR's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, BLTE has a market cap of 2.2B. Regarding current trading prices, ACGN is priced at $0.38, while BLTE trades at $67.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas BLTE's P/E ratio is -47.22. In terms of profitability, ACGN's ROE is -0.68%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, ACGN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check BLTE's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, ACGN is priced at $0.38, while AGIO trades at $37.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas AGIO's P/E ratio is 3.34. In terms of profitability, ACGN's ROE is -0.68%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, ACGN is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check AGIO's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, ACGN is priced at $0.38, while IBRX trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas IBRX's P/E ratio is -4.96. In terms of profitability, ACGN's ROE is -0.68%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, ACGN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check IBRX's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, ACGN is priced at $0.38, while GLPG trades at $32.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas GLPG's P/E ratio is -6.47. In terms of profitability, ACGN's ROE is -0.68%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, ACGN is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check GLPG's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, ACGN is priced at $0.38, while APGE trades at $36.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas APGE's P/E ratio is -10.05. In terms of profitability, ACGN's ROE is -0.68%, compared to APGE's ROE of -0.19%. Regarding short-term risk, ACGN is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check APGE's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, ACGN is priced at $0.38, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas CALT's P/E ratio is -22.73. In terms of profitability, ACGN's ROE is -0.68%, compared to CALT's ROE of -1.67%. Regarding short-term risk, ACGN is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check CALT's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, FOLD has a market cap of 2.1B. Regarding current trading prices, ACGN is priced at $0.38, while FOLD trades at $6.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas FOLD's P/E ratio is -57.75. In terms of profitability, ACGN's ROE is -0.68%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, ACGN is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check FOLD's competition here

ACGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ACGN stands at 3.2M. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, ACGN is priced at $0.38, while DNLI trades at $14.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ACGN currently has a P/E ratio of -0.04, whereas DNLI's P/E ratio is -5.37. In terms of profitability, ACGN's ROE is -0.68%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, ACGN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ACGN.Check DNLI's competition here